Phase II study of Bevacizumab with SOX (S-1 plus L-OHP) as second-line therapy in metastatic colorectal cancer
Ontology highlight
ABSTRACT: Interventions: Bevacizumab with SOX (S-1 plus L-OHP) repeat every 21 days until discontinuance criteria.
Primary outcome(s): Response Rate
Study Design: Single arm Non-randomized
DISEASE(S): Metastatic Colorectal Cancer
PROVIDER: 2620638 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA